GlassScriptPhysician profile
Michele Innocent
NPI 1134666274
$27,345.06
in general payments reported to CMS, 2019-2025
74 companies · $9,550 in 2025
The $9,550 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,240 · 2022: $3,842 · 2023: $4,832 · 2024: $6,881 · 2025: $9,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $4,498 · Long Term Medical Supply Or Device Loan: $1,748 · Education: $773 · Travel and Lodging: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,838.52 |
| Consulting Fee | $4,497.50 |
| Long Term Medical Supply Or Device Loan | $1,748.45 |
| Education | $773.09 |
| Travel and Lodging | $404.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Legend Biotech USA INC. | $4,083.98 | 2024-2025 | Carvykti |
| Janssen Biotech, INC. | $3,094.10 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Novartis Pharmaceuticals Corporation | $2,939.84 | 2021-2025 | Kisqali, Piqray |
| Incyte Corporation | $1,335.50 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $1,253.12 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,063.64 | 2021-2025 | Tagrisso, Enhertu, Calquence |
| Celgene Corporation | $1,008.52 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Adaptive Biotechnologies Corporation | $941.78 | 2022-2025 | Clonoseq |
| Genzyme Corporation | $807.32 | 2021-2025 | |
| Pfizer INC. | $799.60 | 2021-2025 | |
| Seagen INC. | $727.81 | 2021-2025 | Tivdak, Padcev, Tukysa |
| Daiichi Sankyo INC. | $588.75 | 2021-2025 | Enhertu, Datroway |
| Abbvie INC. | $533.88 | 2021-2025 | |
| Astellas Pharma US INC | $521.03 | 2021-2025 | Xtandi, Vyloy, Xospata |
| Takeda Pharmaceuticals U.S.A., INC. | $503.05 | 2021-2025 | Ninlaro, Alunbrig, Vpriv |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $499.84 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $499.68 | 2021-2025 | |
| Eisai INC. | $436.08 | 2021-2025 | |
| Karyopharm Therapeutics INC. | $407.02 | 2021-2025 | Xpovio |
| Genentech USA, INC. | $377.22 | 2021-2025 | Phesgo, Polivy, Tecentriq Hybreza |
| Amgen INC. | $321.75 | 2021-2023 | Kyprolis, Vectibix, Xgeva |
| Ipsen Biopharmaceuticals, INC | $282.77 | 2021-2025 | Onivyde, Tazverik, Somatuline Depot |
| Tersera Therapeutics LLC | $280.27 | 2021-2025 | Zoladex |
| Emd Serono, INC. | $253.37 | 2022-2025 | Bavencio, Tepmetko |
| Alexion Pharmaceuticals, INC. | $240.48 | 2023-2025 | Ultomiris |
| Puma Biotechnology, INC. | $190.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $176.51 | 2021-2025 | Opdivo, Reblozyl |
| Lilly USA, LLC | $170.39 | 2022-2024 | Jaypirca, Verzenio, Retevmo |
| Exelixis INC. | $163.28 | 2023-2025 | Cabometyx |
| Deciphera Pharmaceuticals INC. | $157.47 | 2021-2025 | Qinlock, Tgct, Romvimza |
| Beigene USA, INC. | $149.64 | 2021-2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $126.82 | 2021-2023 | Imbruvica, Epkinly |
| Janssen Pharmaceuticals, INC | $125.97 | 2021-2025 | Xarelto |
| Mirati Therapeutics, INC. | $123.68 | 2023-2024 | Krazati |
| Array Biopharma INC | $115.69 | 2021-2024 | Braftovi, Lorbrena, Mektovi |
| Regeneron Healthcare Solutions, INC. | $113.65 | 2022-2024 | Libtayo |
| Dendreon Pharmaceuticals LLC | $112.15 | 2024-2025 | Provenge |
| Aveo Pharmaceuticals, INC. | $108.09 | 2023-2024 | Fotivda |
| Sobi, INC | $106.46 | 2022-2025 | |
| Pharmaessentia USA Corporation | $99.85 | 2022-2025 | Besremi |
| Servier Pharmaceuticals LLC | $92.88 | 2023-2025 | |
| Stemline Therapeutics INC. | $90.18 | 2025 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.82 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $83.00 | 2025 | |
| Myriad Genetic Laboratories, INC. | $71.65 | 2021-2025 | Myrisk |
| Rigel Pharmaceuticals, INC. | $70.49 | 2025 | Tavalisse |
| Agios Pharmaceuticals, INC. | $65.21 | 2022-2025 | Pyrukynd |
| Alnylam Pharmaceuticals INC. | $62.65 | 2022-2023 | Onpattro, Givlaari |
| Taiho Oncology, INC. | $59.57 | 2021-2023 | |
| Coherus Oncology, INC. | $55.04 | 2023 | |
| Foundation Medicine, INC. | $54.96 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $53.06 | 2021-2023 | |
| Pharmacosmos Therapeutics INC. | $51.37 | 2023-2024 | Monoferric |
| Immunogen, INC. | $47.07 | 2023 | Elahere |
| Adc Therapeutics America, INC. | $46.12 | 2024 | |
| Geron Corporation | $45.20 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $43.18 | 2022-2023 | Beleodaq |
| Dova Pharmaceuticals | $42.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $40.45 | 2025 | Vivimusta |
| Recordati_rare_diseases_inc. | $39.11 | 2024 | Sylvant |
| Kyowa Kirin, INC. | $38.74 | 2023-2024 | Poteligeo |
| Iovance Biotherapeutics, INC. | $38.12 | 2024-2025 | Amtagvi |
| G1 Therapeutics, INC. | $31.76 | 2023 | Cosela |
| Sumitomo Pharma America, INC. | $28.90 | 2024 | Orgovyx |
| Blue Earth Diagnostics | $28.46 | 2023 | |
| Morphosys, US INC. | $27.90 | 2021 | |
| Gilead Sciences, INC. | $23.90 | 2022 | |
| Delcath Systems | $21.26 | 2025 | Hepzato Kit |
| Beone Medicines USA, INC. | $19.02 | 2025 | Brukinsa |
| Heron Therapeutics, INC. | $16.47 | 2021 | |
| Shield Therapeutics INC | $13.79 | 2024 | |
| Sirtex Medical INC | $8.47 | 2022 | |
| Organon LLC | $4.81 | 2023 | Ontruzant |
| Clovis Oncology, INC. | $2.05 | 2022 |
Drugs and devices associated with these payments
Kisqali $1,963Carvykti $1,308Keytruda $832Tecvayli $701Darzalex $678Jakafi $665Enhertu $548Clonoseq $526Reblozyl $499Sarclisa $461Nubeqa $387Pluvicto $345Rybrevant $343Xpovio $281Xofigo $261Jemperli $252Erleada $250Elahere $244Tukysa $241Ultomiris $240Talvey $240Lenvima $234Zoladex $231Xtandi $221Tagrisso $216Vitrakvi $216Piqray $192Lynparza $192Venclexta $190Ibrance $187Phesgo $166Tivdak $166Opdivo $164Elrexfio $153Ninlaro $149Calquence $145Stivarga $144Pomalyst $134Imbruvica $131Adcetris $128Zejula $127Krazati $124Padcev $120Lorbrena $119Qinlock $114Provenge $112Jaypirca $110Fotivda $108Epkinly $106Vyloy $104Scemblix $103Lutathera $102Onivyde $101Bavencio $99.28Talzenna $96.46Verzenio $94.64Orgovyx $93.02Welireg $92.39Braftovi $91.54Mektovi $91.54Orserdu $90.18Alunbrig $87.42Vpriv $86.09Ojjaara $83.47Brukinsa $81.81Retevmo $79.11Bosulif $70.49Tavalisse $70.49Cablivi $70.05Tazverik $69.49Tibsovo $68.34Cabometyx $68.28Xalkori $65.96Akeega $60.32Doptelet $60.25Inlyta $60.01Besremi $57.18Udenyca $55.04Iclusig $54.33Polivy $54.01Monjuvi $52.76Monoferric $51.37Pyrukynd $50.75Somatuline Depot $47.85Elitek $47.20Rytelo $45.20Nerlynx $43.34Vivimusta $40.45Sylvant $39.11Opdualag $38.75Poteligeo $38.74Amtagvi $38.12Libtayo $37.27Oxbryta $37.17Vonvendi $36.69Vonjo $33.54Kyprolis $33.10Cosela $31.76Ayvakit $30.62Xospata $30.39
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Innocent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.